-+ 0.00%
-+ 0.00%
-+ 0.00%

HARBOUR BIOMED PARTNER, SOLSTICE ONCOLOGY, ANNOUNCES $225 MILLION SERIES A FINANCING TO ADVANCE PORUSTOBART, A NEOADJUVANT IMMUNO-ONCOLOGY THERAPY

Reuters·09/09/2026 11:12:48

Please log in to view news